Effects of raloxifene, one of the selective estrogen receptor modulators, on pituitary-ovary axis and prolactin in postmenopausal women
Journal
Endocrine
Journal Volume
23
Journal Issue
2-3
Pages
215-218
Date Issued
2004
Author(s)
Abstract
To investigate the clinical effects of raloxifene, one of the selective estrogen receptor modulators (SERMs), on the pituitary-ovary axis and prolactin, a prospective, randomized, double-blinded study on 59 healthy postmenopausal women was performed. Forty-eight women received raloxifene 60 mg daily. The other 11 received combined conjugated equine estrogen 0.625 mg and medroxyprogesterone acetate 5 mg daily (CCEP) as active controls. Serum follicle stimulating hormone (FSH), luteinizing hormone (LH), estradiol (E2), and prolactin were measured at baseline and 1 yr after treatment. The mean levels of FSH and LH were significantiy decreased in the raloxifene group (FSH: -10.7%; p < 0.01, LH: -10.3%; p < 0.05) and CCEP group (FSH: -53.7%, p < 0.001; LH: -46.8%, p < 0.001). The prolactin level decreased in the raloxifene group but not in the CCEP group (-17.0%; p < 0.001 vs +13.3%, p = no significance; NS). Consequently, long-term administration of raloxifene up to 1 yr decreases serum prolactin level significantly and may be a therapeutic alternative for postmenopausal osteoporotic women with hyperprolactinemia.
SDGs
Other Subjects
conjugated estrogen; estradiol; follitropin; luteinizing hormone; medroxyprogesterone; prolactin; raloxifene; selective estrogen receptor modulator; conjugated estrogen; estradiol; follitropin; luteinizing hormone; medroxyprogesterone acetate; prolactin; raloxifene; selective estrogen receptor modulator; adult; article; clinical trial; controlled clinical trial; controlled study; double blind procedure; drug effect; dyspepsia; female; flatulence; follitropin blood level; headache; human; hyperprolactinemia; hypophysis; luteinizing hormone blood level; normal human; osteoporosis; ovary; postmenopause; priority journal; prolactin blood level; randomized controlled trial; spotting; statistical significance; blood; drug antagonism; middle aged; oral drug administration; Administration, Oral; Double-Blind Method; Estradiol; Estrogens, Conjugated (USP); Female; Follicle Stimulating Hormone; Humans; Luteinizing Hormone; Medroxyprogesterone 17-Acetate; Middle Aged; Ovary; Pituitary Gland; Postmenopause; Prolactin; Raloxifene; Selective Estrogen Receptor Modulators
Type
journal article